Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cardiome Pharma Corp (CRME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,247
  • Shares Outstanding, K 34,870
  • Annual Sales, $ 24,010 K
  • Annual Income, $ -29,810 K
  • 36-Month Beta 0.19
  • Price/Sales 3.46
  • Price/Cash Flow N/A
  • Price/Book 8.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.90
  • Most Recent Earnings -0.20 on 11/14/17
  • Next Earnings Date 05/15/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.24
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +19.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.06 +13.11%
on 04/27/18
2.45 -4.90%
on 05/16/18
-0.03 (-1.27%)
since 04/16/18
3-Month
1.37 +70.07%
on 03/01/18
2.45 -4.90%
on 05/16/18
+0.86 (+58.50%)
since 02/16/18
52-Week
1.29 +80.62%
on 11/16/17
4.84 -51.86%
on 07/17/17
-1.09 (-31.87%)
since 05/16/17

Most Recent Stories

More News
Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV

Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV

CRME : 2.33 (-2.10%)
COM.TO : 2.95 (-2.64%)
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in China

NASDAQ: CRME TSX: COM

CRME : 2.33 (-2.10%)
COM.TO : 2.95 (-2.64%)
Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.

Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.

CPH.TO : 1.75 (unch)
CRME : 2.33 (-2.10%)
CPHRF : 1.3950 (+1.01%)
Correvio Reports First Quarter 2018 Financial Results

Management to Host Conference Call and Webcast Today, May 15, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific)

STDY : 4.80 (+1.59%)
CRME : 2.33 (-2.10%)
COM.TO : 2.95 (-2.64%)
Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma

Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma

CPH.TO : 1.75 (unch)
CRME : 2.33 (-2.10%)
CPHRF : 1.3950 (+1.01%)
Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals

Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals

CPH.TO : 1.75 (unch)
CRME : 2.33 (-2.10%)
COM.TO : 2.95 (-2.64%)
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call

Shareholders Approve Cipher Acquisition of Canadian Business Portfolio of Cardiome

CRME : 2.33 (-2.10%)
COM.TO : 2.95 (-2.64%)
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference

Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference

CRME : 2.33 (-2.10%)
COM.TO : 2.95 (-2.64%)
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®

NASDAQ: CRME TSX: COM

CRME : 2.33 (-2.10%)
COM.TO : 2.95 (-2.64%)
Cardiome Announces Fifteen Xydalba and Zevtera® Abstracts at ECCMID 2018

NASDAQ: CRME TSX: COM

CRME : 2.33 (-2.10%)
COM.TO : 2.95 (-2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CRME with:

Business Summary

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.

See More

Key Turning Points

2nd Resistance Point 2.51
1st Resistance Point 2.42
Last Price 2.33
1st Support Level 2.27
2nd Support Level 2.21

See More

52-Week High 4.84
Fibonacci 61.8% 3.48
Fibonacci 50% 3.07
Fibonacci 38.2% 2.65
Last Price 2.33
52-Week Low 1.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar